Cantor Fitzgerald Predicts XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Xenon Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the biopharmaceutical company will post earnings of ($2.41) per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same quarter in the previous year, the firm earned ($0.73) earnings per share.

A number of other research analysts also recently weighed in on XENE. HC Wainwright restated a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $56.00.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $39.98 on Thursday. Xenon Pharmaceuticals has a 1 year low of $35.53 and a 1 year high of $50.99. The company has a market cap of $3.05 billion, a P/E ratio of -14.18 and a beta of 1.20. The stock’s fifty day moving average price is $40.23 and its 200-day moving average price is $40.79.

Insider Activity

In related news, Director Gary Patou sold 4,891 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the sale, the director now owns 23,573 shares of the company’s stock, valued at $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Sherry Aulin sold 18,709 shares of Xenon Pharmaceuticals stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Company insiders own 5.52% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in shares of Xenon Pharmaceuticals by 2.2% during the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock worth $272,349,000 after acquiring an additional 149,511 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 2.3% during the second quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock valued at $172,315,000 after purchasing an additional 97,732 shares during the period. Wellington Management Group LLP grew its holdings in shares of Xenon Pharmaceuticals by 0.4% in the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock worth $151,317,000 after purchasing an additional 15,226 shares during the last quarter. Braidwell LP increased its stake in Xenon Pharmaceuticals by 5.7% in the 3rd quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company’s stock worth $106,585,000 after buying an additional 146,682 shares during the period. Finally, Janus Henderson Group PLC boosted its position in Xenon Pharmaceuticals by 144.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock valued at $100,506,000 after buying an additional 1,507,135 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.